Dermatologic Surgery

Use of Autologous, Noncultured Melanocyte–Keratinocyte Transplantation in Patients With Stable Genital Leucoderma No abstract available

A Closure Option for Sinuous Hairline Preservation on the Upper Forehead No abstract available

Sharp Debulking and Nonbeveled Layers in Mohs Micrographic Surgery, A Video Walkthrough: How We Do It No abstract available

Vulvar Lichen Sclerosus: Consider Treatment With Heterologous Type I Collagen No abstract available

Efficacy, Patient-Reported Outcomes, and Safety in Male Subjects Treated With OnabotulinumtoxinA for Improvement of Moderate to Severe Horizontal Forehead Lines BACKGROUND Men represent a growing segment of the facial aesthetic market. OBJECTIVE To evaluate investigator-assessed efficacy, patient-reported outcomes, and safety after onabotulinumtoxinA treatment of forehead lines (FHL) in men. METHODS Subjects with moderate to severe FHL received onabotulinumtoxinA (frontalis: 20 U; glabellar complex: 20 U, with/without 24 U in crow's feet regions) or placebo in 6-month, double-blind periods of 2 pivotal trials. Results for men were pooled. RESULTS Men comprised 12% (140/1,178) of subjects. Day 30 male responder rates for achieving at least 1-grade Facial Wrinkle Scale (FWS) improvement at maximum eyebrow elevation and at rest were 98.2% and 93.3%, respectively; a significant difference in responder rates was maintained versus placebo (p < .05) through Day 150. Despite men having proportionately more severe FHL at baseline, 81.8% and 79.8% achieved Day 30 FWS ratings of none or mild at maximum eyebrow elevation and at rest, respectively (p < .05); significance versus placebo was maintained through Day 120. Men reported high satisfaction rates and improved psychological impacts. No new safety signals were detected. CONCLUSION Standard dosing and administration of onabotulinumtoxinA significantly improved static and dynamic FHL appearance, despite men having proportionately more severe FHL at baseline. Men reported high satisfaction and appearance-related psychological impact improvements. Address correspondence and reprint requests to: Terrence C. Keaney, MD, SkinDC, 1525 Wilson Boulevard, Suite 125, Arlington, VA 22209, or e-mail: terrencekeaney@gmail.com Supported by Allergan plc, Dublin, Ireland. Editorial support for this article was provided by A. Drinkwater of Peloton Advantage, Parsippany, New Jersey, and was funded by Allergan plc. T.C. Keaney has served on advisory boards and speakers' bureaus and serves as a consultant for Allergan plc. M. Cavallini and C. Leys serve as investigators for Allergan plc. A. Rossi serves as a consultant and on an advisory board for, and has received honoraria from, Allergan plc. A. Drinkwater is an employee of Peloton Advantage, who received funding from Allergan plc for medical editing and editorial support. S. Manson Brown, J.K. Garcia, and C. Mao are employees of Allergan plc and may own stock/options in the company. © 2019 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.

Efficacy and Safety of 3 New Resilient Hyaluronic Acid Fillers, Crosslinked With Decreased BDDE, for the Treatment of Dynamic Wrinkles: Results of an 18-Month, Randomized Controlled Trial Versus Already Available Comparators BACKGROUND Three new hyaluronic acid (HA)-based fillers made of long chains crosslinked with reduced amounts of 1,4-butanediol diglycidyl ether (BDDE) were developed for the treatment of dynamic facial areas. Their resilience and increased stretching ability were optimized to ease injectors' practice and provide patients with most natural aesthetic results. OBJECTIVE This study aimed at evaluating the efficacy, durability, and safety of these resilient HA fillers versus commercially available comparator gels. METHODS A prospective, monocentric, split-face, double-blinded, randomized, controlled trial was performed on 90 subjects presenting moderate to severe bilateral nasolabial folds (NLFs). Efficacy parameters were assessed over 18 months, including improvement on the Wrinkle Severity Rating Scale and Global Aesthetic Improvement Scale, as well as quantitative imaging and analysis of NLF correction. Physicians' and subjects' satisfaction, together with safety, were assessed throughout the study. RESULTS The new HA fillers offered efficacy and safety profiles at least equivalent to comparators. These dynamic facial fillers elicited higher satisfaction immediately after injection but also on the long run, according to both investigators and subjects. CONCLUSION This pilot trial demonstrated the numerous benefits of 3 new resilient HA fillers with decreased BDDE crosslinking in the treatment of dynamic wrinkles. Address correspondence and reprint requests to: Berthold Rzany, ScM, RZANY & HUND, Kurfürstendamm 183, Berlin 10707, Germany, or e-mail: rzany@kudamm183.de Materials and funding for this study were provided by TEOXANE Laboratories. Berthold Rzany is a consultant for Merz Aesthetics. © 2019 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.

Treatment of Nasal Scars Caused by Skin Necrosis From Hyaluronic Acid Injections Using Stromal Vascular Fraction Gel, a Novel Fat Tissue–Derived Product No abstract available

Editorial No abstract available

Multiple Squamous Neoplasms Arising in a Red Tattoo After Laser Tattoo Removal No abstract available

A Rare Frightening Complication Does Not Follow Expectations No abstract available

Alexandros Sfakianakis
Anapafseos 5 . Agios Nikolaos
Crete.Greece.72100
2841026182

6948891480

alsfakia@gmail.com